Morphic Therapeutic

89 articles with Morphic Therapeutic

• Morphic to Present at TD Cowen 43rd Annual Health Care Conference

  3/3/2023

  Morphic Therapeutic today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference.

• Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

  2/23/2023

  Morphic Therapeutic today reported corporate highlights and financial results for the full year 2022.

• Morphic to Present at SVB Leerink Global Healthcare Conference

  2/14/2023

  Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink Global Healthcare conference including a hosted fireside chat.

• 

  Morphic Loses Another Big Pharma as J&J Bails on Research Deal

  1/23/2023

  J&J's Janssen terminated its integrin research collaboration with Morphic Therapeutics. This follows the June 2022 termination of a partnership with AbbVie.

• Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/5/2023

  Morphic Therapeutic today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41 st  Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST.

• Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative ColitisFirst patient dosed in global study of oral α4β7 integrin inhibitor

  11/22/2022

  Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the EMERALD-2 phase 2b study of MORF-057 in ulcerative colitis (UC) has commenced with the first patient receiving MORF-057.

• Morphic Announces Participation in 2022 Jefferies London Healthcare Conference

  11/9/2022

  Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16th, at 10:55 AM GMT.

• Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022

  11/2/2022

  Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter of 2022.

• Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

  10/25/2022

  Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the presentation of data from a new MORF-057 phase 1 study at the American College of Gastroenterology (ACG) Annual Meeting 2022 that strongly support the ongoing EMERALD-1 phase 2a study and the upcoming EMERALD-2 phase 2b study of MORF-057.

• Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections

  10/24/2022

  Morphic Therapeutic announced the completion of targeted enrollment of 30 patients ahead of schedule for the main cohort of the EMERALD-1 phase 2a study of MORF-057 in patients with moderate to severe ulcerative colitis.

• Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

  10/10/2022

  Morphic Therapeutic today announced the presentation of new phase 1 data from MORF-057 phase 1 studies at the United European Gastroenterology (UEG) Week 2022.

• Morphic Announces Participation in 2022 Wells Fargo Healthcare Conference

  9/1/2022

  Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside chat at the Wells Fargo Healthcare Conference on Thursday, September 8that 10:25 AM ET.

• Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022

  8/3/2022

  Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the second quarter of 2022.

• 

  AbbVie Seeks New Indication for Migraine Drug Qulipta, Drops Deal with Morphic

  6/22/2022

  AbbVie filed a supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for Qulipta for the preventative treatment of migraine.

• Morphic to Present at 2022 Jefferies Global Healthcare Conference

  6/9/2022

  Morphic Therapeutic announced that Bruce Rogers, Ph.D., President of Morphic, will give a corporate presentation at the Jefferies Global Healthcare Conference on Thursday, June 9th at 2:00 PM ET.

• Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

  5/18/2022

  Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced that Joanne Gibbons has been named Senior Vice President of Regulatory Affairs.

• Morphic Announces Participation in 2022 RBC Capital Markets Global Healthcare Conference

  5/17/2022

  Morphic Therapeutic announced that members of its management team will participate in a fireside chat at the RBC Capital Markets on Wednesday, May 18that 8:00 AM ET.

• Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer

  5/12/2022

  Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced two key executive appointments.

• Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022

  5/4/2022

  Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, reported corporate highlights and financial results for the first quarter of 2022.

• Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development

  4/6/2022

  Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leader Aaron Pelta promoted to Senior Vice President, Business and Corporate Development; leading portfolio, commercial, and partnering strategy.